Mountain Crest Acquisition Corp. II (MCAD) Shareholders Approve Better Therapeutics Deal

Mountain Crest Acquisition Corp. II (NASDAQ:MCAD) announced in a press release that it secured shareholder approval of its combination with biopharmaceutical firm Better Therapeutics in a special meeting held earlier today. Although the press release did not disclose redemption amounts, MCAD traded below $10 throughout its redemption deadline October 25.  However, the SPAC reached a
Read More